Transgenic mice containing SOCS-5 cytokine signalling suppressor gene disruptions
OwnerKeith D. Allen, Mark Moore +2inventors
InventorsKeith D. Allen, Mark Moore, Qin Zhang, Christopher J. Kirk
Life of this patent
Estimating the term…
Abstract
The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a SOCS-5 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
Claims34
A transgenic mouse comprising a disruption in a SOCS-5 gene.
A transgenic mouse comprising a disruption in a SOCS-5 gene, wherein there is no native expression of endogenous SOCS-5 gene.
A method of producing a transgenic mouse comprising a disruption in a SOCS-5 gene, the method comprising:
- (a) providing a murine stem cell comprising a disruption in a SOCS-5 gene;
- and
- (b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse.
A targeting construct comprising:
- (a) a first polynucleotide sequence homologous to at least a first portion of a SOCS-5 gene;
- (b) a second polynucleotide sequence homologous to at least a second portion of a SOCS-5 gene;
- and
- (c) a selectable marker.
A cell comprising a disruption in a SOCS-5 gene.
A method of identifying an agent that modulates a phenotype associated with a disruption in a SOCS-5 gene, the method comprising:
- (a) contacting a test agent with SOCS-5;
- and
- (b) determining whether the agent modulates SOCS-5.
A method of identifying an agent that modulates a phenotype associated with a disruption in a SOCS-5 gene, the method comprising:
- (a) administering a test agent to an animal exhibiting a phenotype associated with a disruption in a SOCS-5 gene;
- and
- (b) determining whether the agent modulates the phenotype.
A method of identifying a potential therapeutic agent for the treatment of a disease analogous to a phenotype associated with a disruption in a SOCS-5 gene, the method comprising:
- (a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a SOCS-5 gene;
- and
- (b) determining whether the potential therapeutic agent modulates the disease, wherein modulation of the disease identifies a potential therapeutic agent for the treatment of the disease.
A method of identifying a potential therapeutic agent for the treatment of a disease analogous to a phenotype associated with a disruption in a SOCS-5 gene, the method comprising:
- (a) contacting the potential therapeutic agent with SOCS-5;
- (b) determining whether the agent modulates SOCS-5, wherein modulation of SOCS-5 identifies a potential therapeutic agent for the treatment of the disease.
A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a SOCS-5 gene, the method comprising:
- (a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a SOCS-5 gene;
- and
- (b) evaluating the effects of the agent on the transgenic mouse.
A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a SOCS-5 gene, the method comprising:
- (a) contacting the potential therapeutic agent with SOCS-5;
- (b) evaluating the effects of the agent on the SOCS-5.
A therapeutic agent for treating a disease analogous to a phenotype associated with a disruption in a SOCS-5 gene, wherein the agent modulates SOCS-5.
A therapeutic agent for treating a disease analogous to a phenotype associated with a disruption in a SOCS-5 gene, wherein the agent is an agonist or antagonist of SOCS-5.
A pharmaceutical composition comprising a SOCS-5 gene or SOCS-5.
A method of preparing a pharmaceutical composition for a condition associated with a function of SOCS-5, the method comprising:
- (a) identifying a compound that modulates SOCS-5;
- (b) synthesizing the identified compound;
- and
- (c) incorporating the compound into a pharmaceutical carrier.
Phenotypic data associated with a transgenic mouse comprising a disruption in a SOCS-5 gene, wherein the phenotypic data is in an electronic database.
Dependencies are inferred from the claim text.